Evidence map›Paper›PMID 21160030›Full record

ArticleAmerican journal of physiology. Cell physiology2011

20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells.

Andrzej T Slominski, Tae-Kang Kim, Zorica Janjetovic, Robert C Tuckey, Radoslaw Bieniek, Junming Yue, Wei Li, Jianjun Chen, Minh N Nguyen, Edith K Y Tang and 3 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in American journal of physiology. Cell physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Evolutionary formation of melatonin and vitamin D in early life forms: insects take centre stage.Biological reviews of the Cambridge Philosophical Society · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Metabolic activation of tachysterolFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Non-Musculoskeletal Benefits of Vitamin D beyond the Musculoskeletal System.International journal of molecular sciences · 2021
    Review
  15. 20Frontiers in immunology · 2021
    Article
  16. Article
  17. Review
  18. COVID-19 and Vitamin D: A lesson from the skin.Experimental dermatology · 2020
    Article
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Andrzej T SlominskiDept. of Pathology and Laboratory Medicine, Center for Cancer Research, Univ. of Tennessee Health Science Center, 930 Madison Ave., RM525, Memphis, TN 38163, USA.
Tae-Kang Kim
Zorica Janjetovic
Robert C Tuckey
Radoslaw Bieniek
Junming Yue
Wei Li
Jianjun Chen
Minh N Nguyen
Edith K Y Tang
Duane Miller
Tai C Chen
Michael Holick
University of Tennessee Health Science Center · USUniversity of Western Australia · AUBoston University · US

Funding

Novel Biosynthetic Pathway for Secosteroids and the SkinR01AR052190 · NIAMS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI POSTLETHWAITE, ARNOLD E, SLOMINSKI, ANDRZEJ T · 2006 to 2013
$2.2M
Discovery of Novel Cytotoxic Agents for Advanced MelanomaR15CA125623 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI · 2008 to 2008
$219k
NCI NIH HHS 1R15CA125623-01A2NIAMS NIH HHS R01 AR052190PHS HHS R01A052190
6 · The paper itself

Abstract

20-hydroxyvitamin D(2) [20(OH)D(2)] inhibits DNA synthesis in epidermal keratinocytes, melanocytes, and melanoma cells in a dose- and time-dependent manner. This inhibition is dependent on cell type, with keratinocytes and melanoma cells being more sensitive than normal melanocytes. The antiproliferative activity of 20(OH)D(2) is similar to that of 1,25(OH)(2)D(3) and of newly synthesized 1,20(OH)(2)D(2) but significantly higher than that of 25(OH)D(3). 20(OH)D(2) also displays tumorostatic effects. In keratinocytes 20(OH)D(2) inhibits expression of cyclins and stimulates involucrin expression. It also stimulates CYP24 expression, however, to a significantly lower degree than that by 1,25(OH)(2)D(3) or 25(OH)D(3). 20(OH)D(2) is a poor substrate for CYP27B1 with overall catalytic efficiency being 24- and 41-fold lower than for 25(OH)D(3) with the mouse and human enzymes, respectively. No conversion of 20(OH)D(2) to 1,20(OH)(2)D(2) was detected in intact HaCaT keratinocytes. 20(OH)D(2) also demonstrates anti-leukemic activity but with lower potency than 1,25(OH)(2)D(3). The phenotypic effects of 20(OH)D(2) are mediated through interaction with the vitamin D receptor (VDR) as documented by attenuation of cell proliferation after silencing of VDR, by enhancement of the inhibitory effect through stable overexpression of VDR and by the demonstration that 20(OH)D(2) induces time-dependent translocation of VDR from the cytoplasm to the nucleus at a comparable rate to that for 1,25(OH)(2)D(3). In vivo tests show that while 1,25(OH)(2)D(3) at doses as low as 0.8 μg/kg induces calcium deposits in the kidney and heart, 20(OH)D(2) is devoid of such activity even at doses as high as 4 μg/kg. Silencing of CY27B1 in human keratinocytes showed that 20(OH)D(2) does not require its transformation to 1,20(OH)(2)D(2) for its biological activity. Thus 20(OH)D(2) shows cell-type dependent antiproliferative and prodifferentiation activities through activation of VDR, while having no detectable toxic calcemic activity, and is a poor substrate for CYP27B1.

Indexed as

25-Hydroxyvitamin D 2AnimalsAntineoplastic AgentsCell DifferentiationCell ProliferationCells, CulturedGrowth InhibitorsHL-60 CellsHumansKeratinocytesMelanocytesMiceNeoplasms20-hydroxyvitamin D225-Hydroxyvitamin D 2Antineoplastic AgentsGrowth Inhibitors

Identifiers

PMID21160030
PMCPMC3063966
OpenAlexW2083444816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.